Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyo T Htoo

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
American Journal of Epidemiology|February 2, 2022
Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan DataPhyo T Htoo, Gregory Measer, Robert Orr, et al.
Annals of Internal Medicine|September 27, 2021
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Annals of Internal Medicine|January 17, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Annals of Internal Medicine|November 3, 2025
Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 DiabetesSalvatore Crisafulli, Wajd Alkabbani, Julie M Paik, et al.
Cardiovascular Diabetology|March 19, 2024
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE studyPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
Cardiovascular Diabetology|February 8, 2024
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE studyPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
Diabetologia|March 21, 2024
Effectiveness and safety of empagliflozin: final results from the EMPRISE studyPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
JAMA Network Open|October 20, 2022
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient CharacteristicsPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
American Journal of Epidemiology|February 2, 2022
Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan DataPhyo T Htoo, Gregory Measer, Robert Orr, et al.
Annals of Internal Medicine|September 27, 2021
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Annals of Internal Medicine|January 17, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Annals of Internal Medicine|November 3, 2025
Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 DiabetesSalvatore Crisafulli, Wajd Alkabbani, Julie M Paik, et al.
Cardiovascular Diabetology|March 19, 2024
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE studyPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
Cardiovascular Diabetology|February 8, 2024
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE studyPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
Diabetologia|March 21, 2024
Effectiveness and safety of empagliflozin: final results from the EMPRISE studyPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
JAMA Network Open|October 20, 2022
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient CharacteristicsPhyo T Htoo, Helen Tesfaye, Sebastian Schneeweiss, et al.
Pageof 2